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Background and aims: Interferon-γ release assays (IGRAs) have been recently developed for the 
diagnosis of tuberculosis (TB) infection. The aim of the study is to evaluate the use of a commercial 
IGRA [QuantiFERON-TB Gold In-Tube (QFT-IT)] in the follow-up of children exposed to 
Mycobacterium tuberculosis. 
 
Methods: A prospective study in 170 children at risk for TB infection was carried out. All children 
were tested with QFT-IT and tuberculin skin test (TST).  
 
Results: One hundred and six children (62.4%) had taken therapy for active TB or latent 
tuberculosis infection (LTBI) and had undergone an end-of-therapy control with QFT-IT. 
The QFT-IT became negative in 9/56 (16.1%) children. Neither the age (<o≥ 48 months) nor the 
diagnosis (active or LTBI) seem to be a risk factor for the results becoming negative.   
Quantitative interferon-γ (IFN-γ) values did not decline significantly at the end of the therapy. On 
the other hand, a lower baseline IFN-γ level was more often associated with values of QFT-IT 
becoming negative at the end of the therapy (p=0.047). Moreover, the medians of the baseline IFN-
γ values resulted significantly different between the children with active TB [6.75 (3.67–10.00) 
UI/ml] and those with LTBI [3.25 (1.00-7.98) UI/ml] (p=0.022). 
 
Conclusions: At present, on the basis of our results as well as from published data, we believe that 
QFT-IT can have an important role for the follow-up of children at risk of TB infection. The 
quantitative response of QFT-IT rather than the qualitative results turns out to be important. 
 





The World Health Organization estimates that one third of the world’s population is infected 
with Mycobacterium tuberculosis and that, each year, about 9 million people develop tuberculosis 
(TB) of whom 2 million die [1]. One million of the annual TB cases occur in children [1]. Children 
are significantly more likely than adults to develop TB disease following primary Mycobacterium 
tuberculosis infection [2]. Children, especially those younger than 48 months, are also at much 
greater risk of developing severe clinical features, such as miliary disease and tuberculous 
meningitis [3]. Moreover a significant proportion of TB in adult arise from children with latent 
tuberculosis infection (LTBI) [2]. Treating infectious case as well as identifying children latently 
infected is therefore critical to control TB worldwide [4]. 
The diagnosis of TB infection in children is particularly challenging. To date, the gold 
standard for the diagnosis of TB disease is the detection of Mycobacterium tuberculosis [5]. 
However, smears from sputum or, more often, from gastric aspirates are positive in less than 15% 
of children diagnosed with TB and confirmation by culture is achieved only in less than 40% of 
cases [6,7]. Until recently the tuberculin skin test (TST) has been the only test available for the 
diagnosis of LTBI. The main drawback of the TST is its poor specificity in individuals sensitized by 
prior exposure to non-tuberculous mycobacteria (NTM) or by having been vaccinated with 
Mycobacterium bovis Bacille Calmette-Guérin (BCG) [8,9,10]. Additionally, TST sensitivity may 
be low in young children and in individuals with depressed immunity, malnutrition, or advanced TB 
[9,11].   
New diagnostic blood tests, based on the detection of interferon-gamma (IFN-γ) released by 
specifically sensitized T cells, have been recently developed. They detect in vitro immune response 
to Mycobacterium tuberculosis by measuring, with enzyme-linked immunosorbent assay (ELISA) 
or with immunospot assay (ELISpot), the IFN-γ released from T cells in response to peptide 
antigens that simulate mycobacterial proteins [6,12,13]. The specific peptide antigens now available 
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are the early secreted antigenic target 6-kDa protein (ESAT-6), the culture filtrate protein 10-kDa 
(CFP-10) and the Rv2654 antigen (TB7.7). They are encoded by genomic segments of 
Mycobacterium tuberculosis which are absent from all BCG strains and from most NTM [6,12]. 
Two commercial ELISA-based IFN-γ release assays (IGRAs), Quanti-FERON-TB Gold (QFT-G, 
Cellestis) and the newer in-tube format (QFT-IT, Cellestis), have been both approved in Europe and 
by the United States Food and Drug Administration. A guideline from the Centers for Disease 
Control and Prevention (CDC) recommends the use of QFT-G in adults in all circumstances in 
which the TST is currently used [14]. The United Kingdom National Institute for Health and 
Clinical Exellence (NICE) TB guidelines recommend a two-step strategy for LTBI diagnosis with 
an initial TST, followed by an IFN-γ test in TST positive subjects or in those with less reliable TST 
testing [15].  
Although IGRAs are considered very promising tests, they still leave unresolved issues such 
as the sensitivity and the specificity of these tests in the paediatric age. This issue is partially 
unresolved due to the absence of a gold standard for the LTBI and the frequent negative results in 
the diagnosis of TB disease. The trend in the IFN-γ production in response to specific mycobacterial 
antigens, both in TB disease and LTBI, may give useful indications regarding the diagnostic value. 
Particularly, the results becoming positive after exposure to a case of contagious TB disease, or the 
results becoming negative during the specific treatment, may represent indirect markers of the 
sensibility of these tests. An open question is whether they can be used for monitoring the efficacy 
of anti-tuberculosis treatment. A few studies published on adults and only two in children have 
provided contradictory results [16-20]. Nicol et al. have shown in ELISPOT an initial increase in 
the responses to purified protein derivative (PPD) after one month of therapy, followed by a 
decrease at 3 and 6 months. In contrast they have not found a significant difference in the response 
to ESAT 6 and CFP 10 between the beginning and the end of the treatment [19]. Herrmann et al. 
have not found a qualitative difference in the result of QFT at the end of the therapy. However they 
have shown an increase in the IFN-γ response at day 10 of treatment which might allow the 
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confirmation of a diagnosis. They have also found a decline in IFN-γ values during the treatment 
that, they state, make it possible for clinicians to monitor the effect of preventive or curative therapy 
[20].  
The aim of this study was to determine how the qualitative and quantitative response of QFT-
IT change during the follow-up throughout the treatment in children exposed to Mycobacterial 
tuberculosis. 
 
MATERIALS AND METHODS 
 
Study subject 
Consecutive children (younger than 16 years) at risk for TB infection, who had referred to the 
Department of Paediatrics, University of Florence, Italy, were prospectively enrolled between June 
2005 and June 2009. Patients were recruited from the Infectious Disease outpatient clinic (including 
a clinic dedicated to screening immigrants and internationally adopted children) and from inpatients 
admitted with symptoms suggestive of TB disease. The children eligible for the study were those 
belonging to the following three categories: a) children with clinical suspicion of TB disease; b) 
children in close contact with recently diagnosed cases of contagious TB disease; c) internationally 
adopted or recently immigrated children coming from countries with a high prevalence of TB. A 
maximum of two years was considered as period of recent immigration. Children with congenital or 
acquired immunodeficiency disorders (based on their medical history, clinical examination and/or 
laboratory tests) were excluded from the study. 
 
Study design 
Information regarding socio-demographic data, prior TB exposure, and past medical history 
was obtained from each child’s parents or from medical documents. Children were considered to 
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have been vaccinated with BCG if there was a clear documentation and/or a BCG scar was present. 
In the absence of documentation or a BCG scar the vaccination status was considered unknown.  
All children underwent clinical evaluation, venepuncture for QFT-IT at the beginning and at 
the end of the follow-up, and TST. Chest radiography was performed in all symptomatic children, 
in those with a positive TST, and in all contacts aged less than 5 years [21]. Children with suspected 
pulmonary TB had three sputa or early morning gastric aspirates samples collected for 
Mycobacterium tuberculosis detection (by means of microscopy, polymerase chain reaction and 
culture).  
All results were recorded into the study database. The study was approved by local Ethics 
Committee and all parents of the enrolled patients gave written informed consent. 
 
Methods 
TST was administered according to the Mantoux method by injecting intradermally 5 
tuberculin units (in 0.1 mL) of purified protein derivative (Biocine Test-PPD, Chiron, Siena, Italy) 
into the volar surface of the forearm. The TST result was read by experienced Infectious Disease 
specialists at 72 hours by measuring the transverse diameter of the skin induration at the site of the 
PPD application with a flexible ruler. Following the American Academy of Pediatrics guidelines 
[22], a positive TST was defined as an induration size ≥ 5 mm for children in close contact with 
known or suspected contagious case of TB disease or for children suspected to have TB disease 
(based on clinical evidence and/or chest radiograph) and ≥ 10 mm for children born in countries 
with a high prevalence of TB and recently immigrated. 
TB disease diagnosis was assigned to any child with Mycobacterium tuberculosis cultured or 
detected by microscopy or molecular methods from sputum or gastric aspirate. For culture, both 
solid and liquid media (Löwenstein-Jensen and BACTEC 460TB, BD Biosciences Division, 
Sparks, Md;) were used. For children it is often difficult to obtain a positive result from the above 
investigations [6,7]. As a consequence, the TB disease diagnosis was also assigned to any child 
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with clinical and radiologic evidence of active TB, and with either a history of exposure to an 
infectious case or a positive TST [6,23]. In the absence of a recognized standard, LTBI diagnosis 
was assigned to any child with a positive TST and no clinical, bacteriologic or radiographic 
evidence of active TB [11]. All asymptomatic children with a negative TST were defined as 
uninfected. 
QuantiFERON-TB Gold In-Tube (QFT-IT, manufactured by Cellestis Limited, Carnegie, 
Victoria, Australia) was performed in the immunology laboratory according to the manufacturer’s 
instructions [24]. Laboratory personnel were blinded to the status of the patient and TST result. 
QFT-IT was supplied with three heparinized blood collection tubes precoated with three TB-
specific antigens [ESAT 6, CFP-10 and TB7.7(p4)], a mitogen (phytohemagglutinin), and a 
negative control. The cut-off for a positive test, indicating likely Mycobacterium tuberculosis 
infection, was 0.35 IU/mL of IFN-γ for the TB specific antigen-stimulated plasma sample above the 
amount of IFN-γ in the negative control sample. A positive response to the TB-specific antigens 
without a response to the mitogen was considered valid and positive result. If there was no 
detectable IFN-γ response to the mitogen and the TB specific antigens or if the IFN-γ level in the 
negative control was too high, the test was deemed “indeterminate”. Starting from January 2006, 
quantitative data of IFN-γ response to TB specific antigen and to mitogen were also recorded.  
 
Statistical analysis 
Age, TST size and IFN-γ values were expressed as median and interquartile range (IQR) of 
months, millimeters and IU/mL, respectively. The kappa (k) statistic was used to assess the 
agreement between two tests. Differences in frequencies were evaluated by the Fisher test and the 
X2 test. Mann Whitney test and Kruskal-Wallis test were used to compare the medians. Differences 
between the IFN-γ at the beginning and end of therapy were evaluated by Wilcoxon test for paired 
data. Data were analyzed using SPSS 11.5 (Statistical Package for Social Science, Chicago, III). 




One hundred-seventy children were enrolled in the study. The median age was 76.0 (39.0 -
109.0) months. Their demographic characteristics and the reasons for testing are summarized in 
Table 1.  
The diagnosis of active TB disease was made in 21 (12.3%) children. All these children 
presented with pulmonary disease. One-hundred and three children (60.6%) were diagnosed with 
LTBI and 46 (27.1%) children were defined as uninfected. Table 2 shows the BCG status, the TST 
size, and the QFT-IT results according to diagnosis. 
QFT-IT was positive in 66 (38.8%) children and negative in 101 (59.4%). Three (1.8%) 
children had an indeterminate result. In 115 (68.9%) out of 167 cases there was concurrence of the 
TST and QFT-IT results. The overall agreement between the QFT-IT and the TST (without 
considering the indeterminate results) was low with a k value of 0.361. The median age of children 
with a positive QFT-IT was 97.5 (70.5-123.5) months whereas the median age of those with a 
negative result was 50 (830-99) months. At the time of the diagnosis, the QFT-IT was positive in 17 
of 21 (81.0%) children diagnosed with TB disease. Of the 103 children defined as LTBI according 
to the TST results, 47 (45.6%) had a positive and 54 (52.4%) had a negative QFT-IT result; 2 
(1.9%) children had an indeterminate result. Of the 46 remaining children, defined as uninfected, 43 
(93.5%) were tested negative, 2 (4.3%) were positive and 1 (2.2%) indeterminate. 
The median of the IFN-γ values at the time of the diagnosis in children with LTBI (3.25 
[1.00-7.98] UI/ml) was significantly lower than that of those with TB disease (6.75 [3.67-10.0] 
UI/ml), (p =0.022).  
Follow-up. One hundred and six (62.4%) out of 170 children enrolled into the study had 
taken therapy for active TB or LTBI and had undergone an end-of-therapy control with QFT-IT. 
Four of them had taken the preventive therapy for LTBI, although they had been defined as 
uninfected, because they were very close contact of contagious TB cases. Twenty (11.8%) children, 
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who had been defined as uninfected and had a contact with contagious TB disease, had taken a 
therapy only in the “window period” between the first and the second TST. Twenty-four (14.1%) 
children had a QFT follow-up, but had not taken any therapy. Among these, 2 children with LTBI 
were not treated because one had had an adverse reaction to both Isoniazide (INH) and Rifampicin 
(RMP) and the other was a close contact of an index case who was resistant to all anti-tuberculosis 
therapy. Twenty children had taken therapy for LTBI or active TB, but the end of therapy control 
with QFT-IT was not performed (8 children are still in follow up and 12 children were lost to follow 
up). 
We analyzed, in particular, whether there were qualitative and quantitative changes of QFT-
IT at the beginning and end of therapy. Figure 1 shows the qualitative results. In 91 (85.8%) out of  
106 children treated with specific therapy, the QFT-IT result did not change at the end of the 
therapy. The QFT-IT became negative in nine (16.1%) out of  56 children with a positive QFT-IT at 
the beginning of the therapy and became positive in 4 (8.3%) out of 48 children with previous 
negative result. 
Children with a positive result at the time of the diagnosis were further analyzed in order to 
understand what factors may have an influence on the result becoming negative.  In 47 (83.9%) out 
of  56 children with a positive result at the diagnosis, the QFT-IT result remained positive at the end 
of the therapy. In these children the median of the IFN-γ values at the beginning and at the end of 
the therapy was 5.64 and 4.55 UI/ml respectively. This difference was not statistically significant 
(p=0.474) although a decreasing trend was appreciable. 
One (11.1%) out of 9 children whose result had become negative at the end of the therapy was 
younger than 48 months and 8 (88.9%) children were older than 48 months. Among the children 
whose result had remained positive at the end of the therapy, 5 (10.6%) out of 47 were younger than 
48 months and 42 (89.4%) were older than 48 months. There was no significant difference between 
the two groups in being younger or older than 48 months (p=1.000). 
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Considering the diagnosis,  8 (88.9%) out of  9 children whose result had become negative 
had a diagnosis of LTBI and 1 (11.1%) of active TB. Among the children whose result had 
remained positive at the end of the therapy, 34 (72.3%) out of 47 were diagnosed with LTBI and 13 
(27.7%) with active TB. There was no significant difference between the two groups in having a 
diagnosis of LTBI or active TB. (p=0.424). 
Finally, quantitative IFN-γ values before the treatment were analyzed. The baseline IFN-γ 
value in children whose result had become negative was significantly lower than the IFN-γ value in 
children whose result had remained positive (1.08 [0.66-4.98] UI/ml vs. 5.64 [1.99-9.82] UI/ml 
[p=0.047])  
It was then investigated whether the different therapy may have affected the test result.  
Children with LTBI were treated with INH for 6-9 months (23 children) or with INH and RMP for 
3 months (62 children). In case of contact with contagious TB disease resistant to any of these 
drugs, a scheme with INH, RMP and Pyrazinamide (PZA) for the first 2 months (4 children) was 
used. Children with TB disease were treated with INH and RMP (for 6-10 months) + PZA (for 2 
months) + Ethambutol (EMB) (for 4 months) (4 children). 
Among the children with a positive result before the treatment, the QFT-IT result became 
negative in 3 (3%) out of 8 children treated with INH, in 4 (12.9%) out of 31 children treated with 
INH+RMP, in 1 (16.7%) out of 6 children treated with INH+RMP+PZA and in 1 (9.1%) out of 11 
children treated with INH+RMP+PZA+EMB.  
Table 3 shows the median of the IFN-γ values at the beginning and end of the treatment 
according to the different therapeutic scheme. The IFN-γ values tended to decrease at the end of the 
therapy, although the difference was not statistically significant in any of the therapeutic schemes. 
The follow up of the 24 children (2 with LTBI and 22 defined as uninfected) that were not 
treated was also evaluated. The QFT-IT results in the 2 children with LTBI (one negative and one 
positive) did not change at the end of the therapy. Among the 22 children uninfected, 2 (9%) 
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children had a positive result at the baseline that became spontaneously negative at the follow up. 




This work represents, to date, the pediatric prospective study with the largest number of cases 
evaluating the trend of the IFN-γ production in response to specific mycobacterial antigens in the 
follow-up of children exposed to Mycobacterium tubercolosis. Our results show that the QFT-IT 
becomes negative at the end of the anti-tuberculosis therapy in approximately 16% of the children 
with TB infection and with a positive QFT-IT at the baseline. At the end of the therapy a decrease 
of the quantitative IFN-γ values was also noted, although this was statistically not significative. 
Among the results of this study, particularly relevant is the demonstration that a lower baseline IFN-
γ value was more often associated with values of QFT-IT becoming negative at the end of the 
therapy. Moreover, the baseline IFN-γ value in children with LTBI resulted significantly lower than 
the IFN-γ value in children with TB disease. Finally, the age (being older or younger than 48 
months), the diagnosis (TB disease or LTBI) and the therapeutic scheme do not seem to be a risk 
factor for the results becoming negative.  On the other hand, in a few children diagnosed with LTBI 
a negative QFT-IT at the baseline became positive at the end of the therapy. Probably these children 
had been recently exposed to the infection of Mycobacterium tuberculosis. The discrepancy 
between TST (positive) and QFT-IT (negative) results at the diagnosis, with QFT-IT later becoming 
positive, could be associated to two main reasons: firstly, to a booster effect resulting from the 
infection of Mycobacterium tuberculosis in individuals sensitized by prior exposure to 
mycobacterial antigens (as a consequence of the vaccination with BCG or infection from NTM), 
secondly, to TST effectively becoming positive sooner than QFT-IT. This evidence is not 
confirmed by other data from the literature. If we had followed the NICE guidelines, which indicate 
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that only children with both tests (TST and IGRA) positive should be treated, then these children 
would not have been treated. 
In agreement with our results, Herrmann et al., within a pediatric field, and Sauzullo et al. in 
adults, have demonstrated a decrease of IFN-γ at the end of the therapy which, in their case, results 
statistically significant [20,17]. 
The main difficulties that we met in carrying out our study were due to the high number of 
adopted and immigrated children, since in these cases the information regarding medical history and 
social data were often missing. A limiting factor in our study was that we could investigate a 
relatively small number of children with a diagnosis of active TB. Furthermore, not all the children 
had a control test of QFT-IT and a longer follow-up is missing, specially after the end of the 
therapy. Moreover, it was not available a control group of children with LTBI who were not treated, 
due to ethical reasons.  
At present, on the basis of our results as well as from published data, we believe that QFT-IT 
can have an important role for the follow-up of children at risk of TB infection. In particular, the 
quantitative response of QFT-IT rather than the qualitative results turns out to be important. 
Undoubtedly, long-term studies are necessary in order to confirm the validity of QFT-IT, which 











Table 1: Socio-demographic and clinical characteristics of study population  
 total 
n (%) 




region of origin 
    Italy 
    Sub-Saharian Africa 
    North-Africa 
    Asia 
    Eastern-Europe 
    Latin-America 
 
27   (15.9) 
9     (5.3) 




reason for testing: 
  screening 
      recently immigrated 
      internationally adopted 
  contact 
      immigrants 
      Italians 
adopted 
  clinical suspicion of active pulmonary TB 
      immigrants 
      adopted 
      Italians 
 
 
12   (7.1) 
67   (39.4) 
 
49   (28.8) 
22   (12.9) 
2     (1.2) 
 




TB = tuberculosis 
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Table 2: BCG vaccination status, TST size and QuantiFERON-TB Gold In-Tube result according to 
diagnosis  
 uninfected 
n = 46 
n (%) 
latent TB 
n = 103 
n (%) 
TB disease 
n = 21 
n (%) 
total 




    yes 
    no 






















TST induration diameter (mm) 
    < 5 
    ≥ 5   and < 10 
    ≥ 10 and < 15 






















15   (8.8) 
37   (21.8) 
68   (40.0) 
 
QFT-IT result 
    negative 
    positive 




2   (4.3) 













101  (59.4) 
66  (38.8) 
3    (1.8) 
 





 Figure 1. QuantiFERON-TB Gold In-Tube (QFT-IT) results at the beginning and at the end of the 
anti-tuberculosis therapy. 
 










































Table 3. Median and Range Interquartile (IQR) of interferon-γ (UI/ml) values at the time of the 




 IFN-γ  (UI/ml) 
BEFORE THERAPY 
Median (IQR) 
IFN-γ  (UI/ml) 




INH 8.67 (5.62 -10.82) 5.15 (2.92-7.34) n.s. (0.500) 
INH+RMP 4.12 (1.9-8.3) 4.33 (1.5-8.9) n.s. (0.086) 
INH+RMP+PZA 4.67 (3.96-7.29) 3.34 (2.7-14.76) n.s (0.869) 
INH+RMP+PZA+EMB 6.21 (3.67-15.5) 5.32 (2.51-6.8) n.s. (0.684) 
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